Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Dahut

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Journal of the National Cancer Institute|July 25, 2012
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancerJames L Gulley, Susan F Leitman, William Dahut, et al.
BJU International|April 20, 2007
Anti-angiogenic therapy in renal cell cancerRamaprasad Srinivasan, Andrew J Armstrong, William Dahut, et al.
Investigational New Drugs|July 9, 2002
Suramin's development: what did we learn?Maninderjeet Kaur, Eddie Reed, Oliver Sartor, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 1, 2008
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasmaLokesh Jain, Erin R Gardner, Jürgen Venitz, et al.
American Journal of Therapeutics|March 16, 2005
Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapyNushin F Todd, Ronald Lieberman, James L Gulley, et al.
American Journal of Therapeutics|May 23, 2007
Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literatureRavi A Madan, Ron Lieberman, James L Gulley, et al.
Urology|September 6, 2005
Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancerAnthony V D'Amico, Ming-Hui Chen, Michael C Cox, et al.
Clinical Prostate Cancer|March 30, 2004
National Cancer Institute intramural approach to advanced prostate cancerPhilip M Arlen, William D Figg, James Gulley, et al.
Journal of the American Academy of Dermatology|December 28, 2006
Keratoacanthomas associated with sorafenib therapyHeidi H Kong, Edward W Cowen, Nilofer S Azad, et al.
Cancer|December 8, 2005
Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinomaFlora Rozhansky, Ming-Hui Chen, Michael C Cox, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Journal of the National Cancer Institute|July 25, 2012
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancerJames L Gulley, Susan F Leitman, William Dahut, et al.
BJU International|April 20, 2007
Anti-angiogenic therapy in renal cell cancerRamaprasad Srinivasan, Andrew J Armstrong, William Dahut, et al.
Investigational New Drugs|July 9, 2002
Suramin's development: what did we learn?Maninderjeet Kaur, Eddie Reed, Oliver Sartor, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 1, 2008
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasmaLokesh Jain, Erin R Gardner, Jürgen Venitz, et al.
American Journal of Therapeutics|March 16, 2005
Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapyNushin F Todd, Ronald Lieberman, James L Gulley, et al.
American Journal of Therapeutics|May 23, 2007
Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literatureRavi A Madan, Ron Lieberman, James L Gulley, et al.
Urology|September 6, 2005
Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancerAnthony V D'Amico, Ming-Hui Chen, Michael C Cox, et al.
Clinical Prostate Cancer|March 30, 2004
National Cancer Institute intramural approach to advanced prostate cancerPhilip M Arlen, William D Figg, James Gulley, et al.
Journal of the American Academy of Dermatology|December 28, 2006
Keratoacanthomas associated with sorafenib therapyHeidi H Kong, Edward W Cowen, Nilofer S Azad, et al.
Cancer|December 8, 2005
Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinomaFlora Rozhansky, Ming-Hui Chen, Michael C Cox, et al.
Pageof 7